Previous 10 | Next 10 |
Pgiam/iStock via Getty Images Earnings reports dominated the headlines on Tuesday. IBM (IBM) and HCA Healthcare (HCA) both gained ground in pre-market action following their quarterly releases. PPG Industries (PPG) dropped following the announcement of its financial figures. There were also s...
Shares of the small-cap biotech Ardelyx (NASDAQ: ARDX) fell by a whopping 73.2% in pre-market action Tuesday morning. The drugmaker's stock is tanking today in response to a July 13 letter from the U.S. Food and Drug Administration regarding the company's New Drug Application (NDA) ...
Ardelyx (ARDX) -73% after FDA flags deficiencies in Ardelyx's kidney disease treatment NDASolarWinds (SWI) -37% completes Spin-Off of its MSP business; N-able begins trading as independent, publicly traded company.Allied Healthcare Products (AHPI) -12%.Mer Telemanagement Soluti...
Nenov/iStock via Getty Images Ardelyx (ARDX) has lost ~73.0% in the early trading after the company announced that the FDA had identified deficiencies in its marketing application for tenapanor for the control of serum phosphorus in adults with chronic kidney disease on dialysi...
NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against Ardelyx, Inc. (NASDAQ:ARDX). On July 19, 2021, the Company announced that...
The U.S. FDA flagged deficiencies in Ardelyx's (ARDX) New Drug Application ("NDA") for the control of serum phosphorus in adult patients with chronic kidney disease ("CKD") on dialysis.In the letter, to the drugmaker, the health regulator noted that a key issue is the size of the treatment ef...
Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis PR Newswire FREMONT, Calif. and WALTHAM, Mass. , July 19, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX...
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021 The OPTIMIZE Presentation Highlights Data Showing Tenapanor Allows a Greater Percentage of Previously Uncontrolled Patients to Achieve Targeted Serum Phosphorus Levels The PHREEDOM Presentation Shows Positive ...
Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference PR Newswire FREMONT, Calif. and WALTHAM, Mass. , May 25, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-clas...
News, Short Squeeze, Breakout and More Instantly...
Why The Stock Market Is Down Today Why is the stock market down today? The final week of June and the second quarter has been jam-packed with economic data and inflation-related events. Fed Chair Jerome Powell recently said that the global economy has entered a “new world”...
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners PR Newswire HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA ® in the United States in exchange for future hyperphosphatemia royalty payments from ...
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022 PR Newswire WALTHAM, Mass. , June 21, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a missio...